The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)
Open accessAbstract
Thiazolidinedione derivatives are antidiabetic agents that increase the insulin sensitivity of target tissues in animal models of non-insulin-dependent diabetes mellitus. In vitro, thiazolidinediones promote adipocyte differentiation of preadipocyte and mesenchymal stem cell lines; however, the molecular basis for this adipogenic effect has remained unclear. Here, we report that thiazolidinediones are potent and selective activators of peroxisome proliferator-activated receptor gamma (PPAR gamma), a member of the nuclear receptor superfamily recently shown to function in adipogenesis. The most potent of these agents, BRL49653, binds to PPAR gamma with a Kd of approximately 40 nM. Treatment of pluripotent C3H10T1/2 stem cells with BRL49653 results in efficient differentiation to adipocytes. These data are the first demonstration of a high affinity PPAR ligand and provide strong evidence that PPAR gamma is a molecular target for the adipogenic effects of thiazolidinediones. Furthermore, these data raise the intriguing possibility that PPAR gamma is a target for the therapeutic actions of this class of compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Rosiglitazone is the most effective drug among the two approved thiazolidinediones.482”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [482]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
The Steroid and Thyroid Hormone Receptor Superfamily
Evans, R. M. (1988) · Science · doi:10.1126/science.3283939 · Cited by 7,439
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,529
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.
Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., & Spiegelman, B. M. (1994) · Genes & Development · doi:10.1101/gad.8.10.1224 · Cited by 2,181
Luckow, B., & Schütz, G. (1987) · Nucleic Acids Research · doi:10.1093/nar/15.13.5490 · Cited by 1,701
Kliewer, S. A., Forman, B. M., Blumberg, B., Ong, E. S., Borgmeyer, U., Mangelsdorf, D. J., Umesono, K., & Evans, R. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.15.7355 · Cited by 1,400
Self-citationControl of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors
Dreyer, C., Krey, G., Keller, H., Givel, F., Helftenbein, G., & Wahli, W. (1992) · Cell · doi:10.1016/0092-8674(92)90031-7 · Cited by 1,376
Tumor Necrosis Factor α: A Key Component of the Obesity-Diabetes Link
Hotamisligil, G. S., & Spiegelman, B. M. (1994) · Diabetes · doi:10.2337/diab.43.11.1271 · Cited by 1,281
Nuclear receptors enhance our understanding of transcription regulation
GREEN, S., & CHAMBON, P. (1988) · Trends in Genetics · doi:10.1016/0168-9525(88)90108-4 · Cited by 1,043
Cited by
Items 301–400 of 415
PPARs and nonalcoholic fatty liver disease
Liss, K. H. H., & Finck, B. N. (2017) · Biochimie · doi:10.1016/j.biochi.2016.11.009 · Cited by 275
Miyazaki, Y., Glass, L., Triplitt, C., Matsuda, M., Cusi, K., Mahankali, A., Mahankali, S., Mandarino, L. J., & DeFronzo, R. A. (2001) · Diabetologia · doi:10.1007/s001250100031 · Cited by 274
Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks
Knutson, S. K., Chyla, B. J., Amann, J. M., Bhaskara, S., Huppert, S. S., & Hiebert, S. W. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.51 · Cited by 271
“…EMBO Journal VOL 27 | NO 7 | 2008 &2008 European Molecular Biology Organization1024 &2008 European Molecular Biology Organization The EMBO Journal VOL 27 | NO 7 | 2008 1025 insulin and were hypoglycaemic, which is similar to the effects of administration of Pparg agonists (Lehmann et al, 1995).”
MethodQiu, Y.-Y., Zhang, J., Zeng, F.-Y., & Zhu, Y. Z. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106786 · Cited by 271
PPARadigms and PPARadoxes: expanding roles for PPARγ in the control of lipid metabolism
Walczak, R., & Tontonoz, P. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30159-0 · Cited by 270
Shao, D., & Lazar, M. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.21473 · Cited by 270
Sears, I. B., MacGinnitie, M. A., Kovacs, L. G., & Graves, R. A. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.7.3410 · Cited by 270
Endocrine disrupting chemicals and the developmental programming of adipogenesis and obesity
Janesick, A., & Blumberg, B. (2011) · Birth Defects Research Part C: Embryo Today: Reviews · doi:10.1002/bdrc.20197 · Cited by 269
Molecular Mechanisms of Insulin Resistance That Impact Cardiovascular Biology
Wang, C. C. L., Goalstone, M. L., & Draznin, B. (2004) · Diabetes · doi:10.2337/diabetes.53.11.2735 · Cited by 268
Kelly, L. J., Vicario, P. P., Thompson, G. M., Candelore, M. R., Doebber, T. W., Ventre, J., Wu, M. S., Meurer, R., Forrest, M. J., Conner, M. W., et al. (1998) · Endocrinology · doi:10.1210/endo.139.12.6384 · Cited by 268
Crossno, J. T., Majka, S. M., Grazia, T., Gill, R. G., & Klemm, D. J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28510 · Cited by 267
Davies, S. S., Pontsler, A. V., Marathe, G. K., Harrison, K. A., Murphy, R. C., Hinshaw, J. C., Prestwich, G. D., Hilaire, A. S., Prescott, S. M., Zimmerman, G. A., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100878200 · Cited by 266
Gurnell, M., Wentworth, J. M., Agostini, M., Adams, M., Collingwood, T. N., Provenzano, C., Browne, P. O., Rajanayagam, O., Burris, T. P., Schwabe, J. W., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5754 · Cited by 264
Pathophysiological roles of chronic low‐grade inflammation mediators in polycystic ovary syndrome
Rostamtabar, M., Esmaeilzadeh, S., Tourani, M., Rahmani, A., Baee, M., Shirafkan, F., Saleki, K., Mirzababayi, S. S., Ebrahimpour, S., & Nouri, H. R. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.29912 · Cited by 264
Peroxisome Proliferator-Activated Receptor-γ–Mediated Effects in the Vasculature
Duan, S. Z., Usher, M. G., & Mortensen, R. M. (2008) · Circulation Research · doi:10.1161/circresaha.107.164384 · Cited by 263
The Nuclear Receptor Superfamily: A Rosetta Stone for Physiology
Evans, R. M. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0046 · Cited by 262
MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS
OH, W. K., & KANTOFF, P. W. (1998) · Journal of Urology · doi:10.1016/s0022-5347(01)62501-1 · Cited by 260
Crystal Structure of the Ligand Binding Domain of the Human Nuclear Receptor PPARγ
Uppenberg, J., Svensson, C., Jaki, M., Bertilsson, G., Jendeberg, L., & Berkenstam, A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.47.31108 · Cited by 260
Asai, A., & Miyazawa, T. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.11.2932 · Cited by 260
Girnun, G. D., Domann, F. E., Moore, S. A., & Robbins, M. E. C. (2002) · Molecular Endocrinology · doi:10.1210/me.2002-0020 · Cited by 259
PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease
Corona, J. C., & Duchen, M. R. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.06.023 · Cited by 259
Kitamura, S., Miyazaki, Y., Shinomura, Y., Kondo, S., Kanayama, S., & Matsuzawa, Y. (1999) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1999.tb00668.x · Cited by 257
The role of intramuscular lipid in insulin resistance
Hegarty, B. D., Furler, S. M., Ye, J., Cooney, G. J., & Kraegen, E. W. (2003) · Acta Physiologica Scandinavica · doi:10.1046/j.1365-201x.2003.01162.x · Cited by 256
Knouff, C., & Auwerx, J. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0036 · Cited by 256
Lipoatrophy and severe metabolic disturbance in mice with fat-specific deletion of PPARγ
Wang, F., Mullican, S. E., DiSpirito, J. R., Peed, L. C., & Lazar, M. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314863110 · Cited by 255
PPARγ activation in adipocytes is sufficient for systemic insulin sensitization
Sugii, S., Olson, P., Sears, D. D., Saberi, M., Atkins, A. R., Barish, G. D., Hong, S.-H., Castro, G. L., Yin, Y.-Q., Nelson, M. C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912487106 · Cited by 255
The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR)
Peraza, M. A., Burdick, A. D., Marin, H. E., Gonzalez, F. J., & Peters, J. M. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj062 · Cited by 254
Sapieha, P., Stahl, A., Chen, J., Seaward, M. R., Willett, K. L., Krah, N. M., Dennison, R. J., Connor, K. M., Aderman, C. M., Liclican, E., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001571 · Cited by 252
Expression and Characterization of Recombinant Rat Acyl-CoA Synthetases 1, 4, and 5
Kim, J.-H., Lewin, T. M., & Coleman, R. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010793200 · Cited by 252
Seo, J. B., Moon, H. M., Kim, W. S., Lee, Y. S., Jeong, H. W., Yoo, E. J., Ham, J., Kang, H., Park, M.-G., Steffensen, K. R., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3430-3444.2004 · Cited by 250
Metabolic stress-induced joint inflammation and osteoarthritis
Courties, A., Gualillo, O., Berenbaum, F., & Sellam, J. (2015) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2015.05.016 · Cited by 249
Escribano, L., Simón, A.-M., Gimeno, E., Cuadrado-Tejedor, M., López de Maturana, R., García-Osta, A., Ricobaraza, A., Pérez-Mediavilla, A., Del Río, J., & Frechilla, D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.32 · Cited by 235
PPARs as Nuclear Receptors for Nutrient and Energy Metabolism
Hong, F., Pan, S., Guo, Y., Xu, P., & Zhai, Y. (2019) · Molecules · doi:10.3390/molecules24142545 · Cited by 233
Cavaghan, M. K., Ehrmann, D. A., Byrne, M. M., & Polonsky, K. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119562 · Cited by 216
PPARs and lipid ligands in inflammation and metabolism
Harmon, G. S., Lam, M. T., & Glass, C. K. (2011) · Chemical Reviews · doi:10.1021/cr2001355 · Cited by 216
Target Genes of Peroxisome Proliferator-activated Receptor γ in Colorectal Cancer Cells
Gupta, R. A., Brockman, J. A., Sarraf, P., Willson, T. M., & DuBois, R. N. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103779200 · Cited by 215
Self-citationPark, E. J., Park, S. Y., Joe, E.-H., & Jou, I. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210819200 · Cited by 214
Natarajan, C., & Bright, J. J. (2002) · Genes & Immunity · doi:10.1038/sj.gene.6363832 · Cited by 208
Role of transcription factors in mediating post-ischemic cerebral inflammation and brain damage
YI, J., PARK, S., KAPADIA, R., & VEMUGANTI, R. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.04.019 · Cited by 206
Obesity I: Overview and molecular and biochemical mechanisms
Lustig, R. H., Collier, D., Kassotis, C., Roepke, T. A., Kim, M. J., Blanc, E., Barouki, R., Bansal, A., Cave, M. C., Chatterjee, S., et al. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115012 · Cited by 203
Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report
Neuschwander-Tetri, B. A., Isley, W. L., Oki, J. C., Ramrakhiani, S., Quiason, S. G., Phillips, N. J., & Brunt, E. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00009 · Cited by 195
Bell, C. C., Lauschke, V. M., Vorrink, S. U., Palmgren, H., Duffin, R., Andersson, T. B., & Ingelman-Sundberg, M. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074369 · Cited by 201
Hunter, S. J., & Garvey, W. T. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00300-3 · Cited by 200
An alternate binding site for PPARγ ligands
Hughes, T. S., Giri, P. K., de Vera, I. M. S., Marciano, D. P., Kuruvilla, D. S., Shin, Y., Blayo, A.-L., Kamenecka, T. M., Burris, T. P., Griffin, P. R., et al. (2014) · Nature Communications · doi:10.1038/ncomms4571 · Cited by 198
Galli, A., Crabb, D., Price, D., Ceni, E., Salzano, R., Surrenti, C., & Casini, A. (2000) · Hepatology · doi:10.1002/hep.510310117 · Cited by 197
Protecting against vascular disease in brain
Faraci, F. M. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01310.2010 · Cited by 196
Ghorbani, M., Claus, T. H., & Himms-Hagen, J. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00162-7 · Cited by 195
Takeda, K., Toda, K., Saibara, T., Nakagawa, M., Saika, K., Onishi, T., Sugiura, T., & Shizuta, Y. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1760237 · Cited by 182
Regulatory circuits controlling white versus brown adipocyte differentiation
Hansen, J. B., & Kristiansen, K. (2006) · Biochemical Journal · doi:10.1042/bj20060402 · Cited by 178
Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial
Smith, S. R., de Jonge, L., Volaufova, J., Li, Y., Xie, H., & Bray, G. A. (2005) · Metabolism · doi:10.1016/j.metabol.2004.07.008 · Cited by 176
Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes
Blaschke, F., Takata, Y., Caglayan, E., Law, R. E., & Hsueh, W. A. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000191663.12164.77 · Cited by 176
Khandoudi, N., Delerive, P., Berrebi-Bertrand, I., Buckingham, R. E., Staels, B., & Bril, A. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1507 · Cited by 174
Covalent Peroxisome Proliferator-activated Receptor γ Adduction by Nitro-fatty Acids
Schopfer, F. J., Cole, M. P., Groeger, A. L., Chen, C.-S., Khoo, N. K. H., Woodcock, S. R., Golin-Bisello, F., Motanya, U. N., Li, Y., Zhang, J., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.091512 · Cited by 171
Modulation of RXR function through ligand design
Pérez, E., Bourguet, W., Gronemeyer, H., & de Lera, A. R. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.04.003 · Cited by 169
Insulin signaling and glucose transport in insulin resistant human skeletal muscle
Karlsson, H. K. R., & Zierath, J. R. (2007) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-007-0030-9 · Cited by 159
PPARδ as a therapeutic target in metabolic disease
Reilly, S. M., & Lee, C.-H. (2008) · FEBS Letters · doi:10.1016/j.febslet.2007.11.040 · Cited by 164
“However, it is the identification of the lipid-lowering fibrates and insulin sensitizer thiazolidinediones as ligands for PPARα and PPARγ, respectively, that sparks the extensive research in PPAR biology [5, 6].”
BackgroundArlt, W., Auchus, R. J., & Miller, W. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100040200 · Cited by 157
Mechanisms of Androgen Induction of Sebocyte Differentiation
Rosenfield, R. L., Deplewski, D., Kentsis, A., & Ciletti, N. (1998) · Dermatology · doi:10.1159/000017864 · Cited by 156
Patch, R. J., Searle, L. L., Kim, A. J., De, D., Zhu, X., Askari, H. B., O’Neill, J. C., Abad, M. C., Rentzeperis, D., Liu, J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101063h · Cited by 141
Kockx, M., Gervois, P. P., Poulain, P., Derudas, B., Peters, J. M., Gonzalez, F. J., Princen, H. M. G., Kooistra, T., & Staels, B. (1999) · Blood · doi:10.1182/blood.v93.9.2991 · Cited by 139
Ishida, H., Takizawa, M., Ozawa, S., Nakamichi, Y., Yamaguchi, S., Katsuta, H., Tanaka, T., Maruyama, M., Katahira, H., Yoshimoto, K., et al. (2004) · Metabolism · doi:10.1016/j.metabol.2003.11.021 · Cited by 138
Liu, J., Li, H., Burstein, S. H., Zurier, R. B., & Chen, J. D. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.5.983 · Cited by 129
Boden, G., Homko, C., Mozzoli, M., Showe, L. C., Nichols, C., & Cheung, P. (2005) · Diabetes · doi:10.2337/diabetes.54.3.880 · Cited by 129
Whole-genome analyses of whole-brain data: working within an expanded search space
Medland, S. E., Jahanshad, N., Neale, B. M., & Thompson, P. M. (2014) · Nature Neuroscience · doi:10.1038/nn.3718 · Cited by 119
Nuclear receptors as therapeutic targets for Alzheimer's disease
Mandrekar-Colucci, S., & Landreth, G. E. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.594043 · Cited by 126
Role of PPARγ in Regulating Adipocyte Differentiation and Insulin‐Responsive Glucose Uptake
HAMM, J. K., EL JACK, A. K., PILCH, P. F., & FARMER, S. R. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07792.x · Cited by 123
PPAR and Immune System-What Do We Know?
Zhang, X., & Young, H. A. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00057-7 · Cited by 123
“[43] independently found that glitazones were functional ligands for PAPR-γ.”
BackgroundCitral, a component of lemongrass oil, activates PPARα and γ and suppresses COX-2 expression
Katsukawa, M., Nakata, R., Takizawa, Y., Hori, K., Takahashi, S., & Inoue, H. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.07.004 · Cited by 120
Genetic Variation Determines PPARγ Function and Anti-diabetic Drug Response In Vivo
Soccio, R. E., Chen, E. R., Rajapurkar, S. R., Safabakhsh, P., Marinis, J. M., Dispirito, J. R., Emmett, M. J., Briggs, E. R., Fang, B., Everett, L. J., et al. (2015) · Cell · doi:10.1016/j.cell.2015.06.025 · Cited by 117
“…expression nominates mechanistic candidates for several mouse obesity QTLs. Strain-selective PPARγ binding mediates differential responses to antidiabetic drugs Rosiglitazone (rosi) is an antidiabetic TZD drug that functions as a high-affinity activating ligand for PPARγ (Lehmann et al., 1995).”
Neuroinflammation: a potential therapeutic target
Craft, J. M., Watterson, D. M., & Van Eldik, L. J. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.5.887 · Cited by 116
The role of ChREBP in carbohydrate sensing and NAFLD development
Régnier, M., Carbinatti, T., Parlati, L., Benhamed, F., & Postic, C. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00809-4 · Cited by 101
Ito, H., Nakano, A., Kinoshita, M., & Matsumori, A. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000106724.29121.da · Cited by 104
Can literature analysis identify innovation drivers in drug discovery?
Agarwal, P., & Searls, D. B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2973 · Cited by 100
Wang, D., Zhou, Y., Lei, W., Zhang, K., Shi, J., Hu, Y., Shu, G., & Song, J. (2010) · Biology of the Cell · doi:10.1042/bc20090070 · Cited by 100
Lee, C.-H., Kang, K., Mehl, I. R., Nofsinger, R., Alaynick, W. A., Chong, L.-W., Rosenfeld, J. M., & Evans, R. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510815103 · Cited by 98
Harrison, S. A., Thang, C., Bolze, S., Dewitt, S., Hallakou-Bozec, S., Dubourg, J., Bedossa, P., Cusi, K., Ratziu, V., Grouin, J.-M., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.004 · Cited by 96
PFAS and Potential Adverse Effects on Bone and Adipose Tissue through Interactions with PPARγ
Kirk, A. B., Michelsen-Correa, S., Rosen, C., Martin, C. F., & Blumberg, B. (2021) · Endocrinology · doi:10.1210/endocr/bqab194 · Cited by 90
Parham, K. A., Zebol, J. R., Tooley, K. L., Sun, W. Y., Moldenhauer, L. M., Cockshell, M. P., Gliddon, B. L., Moretti, P. A., Tigyi, G., Pitson, S. M., et al. (2015) · The FASEB Journal · doi:10.1096/fj.14-261289 · Cited by 89
Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancer
Fenner, M. H., & Elstner, E. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.557 · Cited by 88
Kim, S.-W., Harney, J. W., & Larsen, P. R. (1998) · Endocrinology · doi:10.1210/endo.139.12.6334 · Cited by 86
Brodbeck, J., Balestra, M. E., Saunders, A. M., Roses, A. D., Mahley, R. W., & Huang, Y. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709906104 · Cited by 86
The peroxisome proliferator-activated receptors at the cross-road of diet and hormonal signalling
Desvergne, B., Ijpenberg, A., Devchand, P. R., & Wahli, W. (1998) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(97)00182-9 · Cited by 83
Töröcsik, D., Szanto, A., & Nagy, L. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.02.002 · Cited by 82
Implementation of BacMam virus gene delivery technology in a drug discovery setting
Kost, T. A., Condreay, J. P., Ames, R. S., Rees, S., & Romanos, M. A. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.02.017 · Cited by 81
Zhao, M., & Chen, X. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.010 · Cited by 80
Troglitazone Antagonizes Metabolic Effects of Glucocorticoids in Humans
Willi, S. M., Kennedy, A., Wallace, P., Ganaway, E., Rogers, N. L., & Garvey, W. T. (2002) · Diabetes · doi:10.2337/diabetes.51.10.2895 · Cited by 77
TF-DUBTACs Stabilize Tumor Suppressor Transcription Factors
Liu, J., Yu, X., Chen, H., Kaniskan, H. Ü., Xie, L., Chen, X., Jin, J., & Wei, W. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c04824 · Cited by 73
Adida, A., & Spener, F. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2006.02.006 · Cited by 72
AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
Lu, Q., Li, X., Liu, J., Sun, X., Rousselle, T., Ren, D., Tong, N., & Li, J. (2019) · Bioscience Reports · doi:10.1042/bsr20181995 · Cited by 69
Peroxisome Proliferator-Activated Receptors and Skin Development
Rosenfield, R. L., Deplewski, D., & Greene, M. E. (2000) · Hormone Research in Paediatrics · doi:10.1159/000053270 · Cited by 69
Clay, C. E., Namen, A. M., Atsumi, G.-I., Trimboli, A. J., Fonteh, A. N., High, K. P., & Chilton, F. H. (2001) · Journal of Investigative Medicine · doi:10.2310/6650.2001.33786 · Cited by 67
Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats
Leclercq, I. A. (2006) · Gut · doi:10.1136/gut.2005.079194 · Cited by 67
Gauthier, A., Vassiliou, G., Benoist, F., & McPherson, R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212989200 · Cited by 66
Bahrami-Nejad, Z., Zhao, M. L., Tholen, S., Hunerdosse, D., Tkach, K. E., van Schie, S., Chung, M., & Teruel, M. N. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.012 · Cited by 65
Domi, E., Uhrig, S., Soverchia, L., Spanagel, R., Hansson, A. C., Barbier, E., Heilig, M., Ciccocioppo, R., & Ubaldi, M. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.4127-15.2016 · Cited by 61
Kobayashi, Y., Ueki, S., Mahemuti, G., Chiba, T., Oyamada, H., Saito, N., Kanda, A., Kayaba, H., & Chihara, J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.5744 · Cited by 57
Eleftheriadou, I., Grigoropoulou, P., Katsilambros, N., & Tentolouris, N. (2008) · Current Diabetes Reviews · doi:10.2174/157339908786241133 · Cited by 55
“PPAR is a member of the nuclear receptor superfamily that regulates the expression of numerous proteins, including those related to inflammation [16, 75, 76].”
BackgroundLDL particle size: an important drug target?
Rajman, I., Eacho, P. I., Chowienczyk, P. J., & Ritter, J. M. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00991.x · Cited by 51
Sadie-Van Gijsen, H., Hough, F. S., & Ferris, W. F. (2013) · Bone · doi:10.1016/j.bone.2013.06.016 · Cited by 48
Tejerina, S., De Pauw, A., Vankoningsloo, S., Houbion, A., Renard, P., De Longueville, F., Raes, M., & Arnould, T. (2009) · Journal of Cell Science · doi:10.1242/jcs.027508 · Cited by 46
Metadata
- Authors
- Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1995-06
- Volume
- 270
- Issue
- 22
- Pages
- 12953-12956
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2047591801
- Cited by
- 3,625
- References
- 30
- FWCI
- 32.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.